Neovacs SA (FR:ALNEV) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neovacs SA, a French biotech firm focusing on inflammatory and autoimmune diseases, has partnered with CNRS’s UTCBS to develop mRNA vaccine delivery methods for asthma treatment. The collaboration, which Neovacs will exclusively fund for 100 k€, aims to create lipid formulations for human and veterinary vaccines. The company is recognized by the CNRS for its R&D efforts in the field of active immunotherapy through its kinoid® technology platform.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.